Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of Nivolumab (ONO-4538) in Japanese Participants with Sepsis or Septic Shock
jRCT2080223545Phase 2
- Sponsor
- Ono Pharmaceutical
- Start
- May 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of nivolumab in sepsis and septic shock, sponsored by Ono Pharmaceutical.
02
Drugs
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on jRCT2080223545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223545.